Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cardium Therapeutics, Inc. (CXM) Builds Diverse Portfolio With Broad Commercialization Opportunities

|Includes: Cardium Therapeutics, Inc (CXM)

It's not something you'd expect to find in a regenerative medicine company's portfolio, but Cardium Therapeutics' To Go Brands healthy nutraceutical supplement business is complementary to the company's overarching mission of meeting unmet medical needs as part of an individual's overall health and wellness.

Cardium in October 2012 acquired the assets, business, and product portfolio of To Go Brands, which develops and markets more than 25 products including nutraceutical powder mixes, supplements, and chews to support healthy lifestyles.

The brand's Healthy To Go product line offers a host of healthy product offerings distributed through mass food and drug channels at retailers such as Whole Foods, CVS, Kroger, GNC, Vitamin Shoppe, and more.

Within Cardium's medical opportunities portfolio is its lead commercial product, Excellagen®, topical gel for wound care management. Excellagen is FDA-approved for the marketing and sale in the United States. In addition to its plans to advance Excellagen's commercial reach in the U.S. and internationally, Cardium plans to develop new extensions for additional wound care applications, and its working to achieve regulatory approval for the marketing and sale of the product in South Korea and the European Union.

The company's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its phase 3 registration study for Generx in Russia.

For more information, visit www.cardiumthx.com or www.togobrands.com

Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html